SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia. ASH 2013.
